Fortress Biotech, Inc. (FBIO)

Over the past six months, the FDA issued a Complete Response Letter for CUTX-101 due to cGMP manufacturing deficiencies in October 2025. In November 2025, Avenue Therapeutics' subsidiary Baergic Bio, Inc. was acquired by Axsome. The FDA accepted the resubmission of the New Drug Application for CUTX-101 in December 2025. In January 2026, Fortress Biotech and Cyprium Therapeutics announced FDA approval of ZYCUBO® for Menkes disease, leading to a Rare Pediatric Disease Priority Review Voucher (PRV). Cyprium Therapeutics entered an agreement to sell the PRV for $205 million in February 2026, and Avenue Therapeutics entered an exclusive worldwide license agreement for ATX-04. In March 2026, Cyprium Therapeutics closed the sale of the PRV for $205 million, with Fortress expecting over $100 million in proceeds and made prepayments on its loan with Oaktree. The company's stock price as of March 27, 2026, was $2.76, a 76.92% increase from March 31, 2025.

Based on historical data, Fortress Biotech, Inc. exhibits some seasonal tendencies. December has been the strongest month, with an average return of 8.51%, while October tends to be the weakest month, averaging a -16.60% return. The overall annual return averages -2.65%, with a consistency score of 51.7, considered "Fair."

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products within the Healthcare sector. The company aims to generate long-term revenue through product sales, equity holdings, and dividend and royalty income. Its product portfolio includes marketed dermatology products for acne and hyperhidrosis, and a pipeline of late-stage product candidates across various therapeutic areas. The company's business activities are divided into Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development, with most revenues from the Dermatology segment.

Fortress Biotech, Inc. is headquartered in Bay Harbor Islands, Florida, with another location in Waltham, Massachusetts, indicating a primary operational focus within the United States. The company also establishes partnerships with leading academic research institutions and biopharmaceutical companies globally to advance its product opportunities.

Information specifically detailing Fortress Biotech, Inc.'s brand reputation is not readily available. Securing FDA approvals for new treatments and strategic sales of assets generally contribute positively to its standing. A Complete Response Letter (CRL) for a drug candidate could temporarily impact perception.

Fortress Biotech, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 16.76% of the company's stock is owned by Institutional Investors, 28.35% by Insiders, and 54.90% by Public Companies and Individual Investors. Major institutional owners include Vanguard Group Inc., Opaleye Management Inc., and BlackRock, Inc. David Jin owns the most shares among individual investors.